Skip to content

Endocrine · Reference monograph

Depot GnRH agonist used in oncology and reproductive endocrinology

Reference compound — not available from Purity Peptides. Shown for research context.

Overview

Triptorelin is a synthetic decapeptide analogue of gonadotropin-releasing hormone in which the glycine at position 6 is replaced by D-tryptophan. This single substitution stabilises a receptor-favoured conformation and protects the peptide from enzymatic cleavage, producing an agonist many times more potent than native GnRH. It originated from the laboratory of Andrew Schally at Tulane University, whose group was central to the isolation of hypothalamic releasing hormones.

Triptorelin is approved in many regions, marketed under names such as Decapeptyl and Trelstar, for indications that include advanced prostate cancer and central precocious puberty. In reproductive endocrinology research it has been studied both as a pituitary down-regulation agent and as a single-exposure trigger of the endogenous LH surge during ovarian stimulation, an approach investigated as an alternative to hCG. Experimental work also uses triptorelin to model sex-steroid deprivation and to probe GnRH receptor expression in tumour tissue. Its long clinical record makes it a well-characterised reference agonist.

Mechanism studied

  1. Triptorelin
  2. GnRH receptor
  3. Pituitary desensitisation
  4. Sex steroids ↓

Triptorelin binds the pituitary GnRH receptor with high affinity and activates Gq-mediated signalling, causing an initial surge of luteinising hormone and follicle-stimulating hormone. When exposure is brief, this surge can be harnessed experimentally, as in studies of agonist-triggered final oocyte maturation. When exposure is sustained, the receptor becomes desensitised and internalised, gonadotropin subunit expression falls and gonadal steroid output declines. The same molecule can therefore either stimulate or suppress the reproductive axis depending on exposure pattern, which is why it is a useful probe of pulsatility in neuroendocrine research.

Research highlights

  • 01Emerged from Andrew Schally's hypothalamic hormone programme, work recognised by the 1977 Nobel Prize.
  • 02The D-tryptophan substitution at position 6 is a textbook example of improving peptide potency and stability.
  • 03Studied extensively as an LH-surge trigger in assisted reproduction research, including work on ovarian hyperstimulation risk.
  • 04Used in rodent models to examine the consequences of sex-steroid deprivation on bone, muscle and behaviour.
  • 05Open questions include the significance of GnRH receptors found on some tumour and extra-pituitary tissues.

Latest published research

1,177 papers on PubMed →

  1. Is there a difference in ovarian hyperstimulation syndrome rates in freeze-all treatment cycles in high-risk patients treated with different GnRH agonist triggers?

    Shah R et al. · Human fertility (Cambridge, England) · 2026 Dec · PMID 42831293

  2. Evaluation of triplet therapy combined with robot-assisted cytoreductive prostatectomy for high-volume metastatic prostate cancer: a multicentre randomised controlled trial protocol

    Yang X et al. · BJU international · 2026 Nov · PMID 42598911

  3. Comparison of cardiovascular events in patients with metastatic hormone sensitive prostate cancer treated with LHRH agonists to LHRH antagonists in the US: A retrospective cohort study

    Titus RS et al. · Urologic oncology · 2026 Oct 18 · PMID 42892580

  4. Proposed Method for Mass Spectrometric Measurement of the Gonadotropin-Releasing Hormone Agonist Deslorelin

    Wei C et al. · Toxics · 2026 Oct 16 · PMID 42931700

  5. Optimizing ovarian stimulation in oocyte donation: exploratory comparison of rhFSH (2:1) versus hp-hMG under PPOS protocols

    Villanueva P et al. · JBRA assisted reproduction · 2026 Sep 28 · PMID 42804682

  6. The two-shot protocol. A randomized controlled trial of a novel two-injection ovarian stimulation strategy

    Donno V et al. · Human reproduction (Oxford, England) · 2026 Sep 25 · PMID 42786378

  7. Sterile abscesses during GnRH agonist therapy for central precocious puberty: a case series and literature review

    Sarli WM et al. · Journal of pediatric endocrinology & metabolism : JPEM · 2026 Sep 25 · PMID 42333572

  8. Pubertal Triptorelin Exposure Alters Hypothalamic Reproductive-Metabolic Integration in a Sex-Specific Manner

    Dimitrijevic D et al. · Biology · 2026 Aug 12 · PMID 42651681

Live feed from PubMed (NCBI) for “Triptorelin”, updated 2026-10-30. Listing a paper is not an endorsement of its findings.

Registered studies

298 on ClinicalTrials.gov →

From the public ClinicalTrials.gov registry for “Triptorelin”, updated 2026-10-30. Shown for research context only; Purity Peptides products are not for human use.

Key references

  1. [1]Manufacturer's prescribing information — FDA / EMA / ANVISA
  2. [2]PubMed — reviews on triptorelin
  3. [3]WADA — Prohibited List of Substances and Methods

FAQ

  • Triptorelin was developed in the laboratory of Andrew Schally at Tulane University during the 1970s and 1980s, as part of systematic work to create GnRH analogues with greater potency and stability than the native hypothalamic decapeptide.

  • A brief exposure to a GnRH agonist provokes an endogenous LH and FSH surge that can induce final oocyte maturation. Researchers have compared this approach with hCG triggering, particularly for its shorter hormonal effect and implications for ovarian hyperstimulation.

  • It is an approved prescription medicine in many countries for indications such as prostate cancer and central precocious puberty. It is also listed under WADA's prohibited substances for male athletes. Research material is supplied strictly for laboratory use.

FOR RESEARCH USE ONLY.Not for human or veterinary use. Not intended to diagnose, treat, cure, or prevent any disease.

Related compounds

WhatsApp